Abstract
Background: This study investigated the relationship between coronary artery ectasia (CAE) and serum levels of high-sensitivity C-reactive protein (Hs-CRP) to test the hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy in CAE.
Method: A prospective analysis was conducted on 217 patients with CAE and 73 healthy controls (NC Group). Participants were grouped by age: CAE-A (≤50 years), CAE-B (50–70 years), and CAE-C (>70 years). All CAE patients received 10 mg of rosuvastatin nightly for six months.
Results: Inflammatory markers were significantly higher in CAE patients than in the NC Group, with the highest levels observed in the youngest group (CAE-A). Following treatment, the CAE-A group showed the most significant reduction in Hs-CRP and IL-6 levels, while the CAE-C group showed negligible change.
Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy.
Introduction
Coronary artery ectasia (CAE) is a cardiovascular abnormality characterized by the dilation of coronary artery segments to at least 1.5 times their normal diameter. While often associated with atherosclerosis, its precise etiology remains elusive, with systemic inflammation identified as a primary pathogenic factor. Currently, there are no standardized clinical guidelines for CAE treatment. This study explores whether patient age influences inflammatory status and the subsequent response to statin therapy, specifically rosuvastatin.
Methods
The researchers analyzed a cohort of 217 CAE patients and 73 healthy controls across three medical centers. CAE was confirmed via coronary angiography. Patients were stratified into three age-based groups:
- CAE-A: ≤50 years (n=60)
- CAE-B: 50–70 years (n=83)
- CAE-C: >70 years (n=74)
All patients in the CAE groups received 10 mg of rosuvastatin nightly for six months. The primary biomarkers measured were high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6).
Results and Key Insights
The Inflammatory Profile of CAE
Baseline data revealed that CAE patients possess significantly higher levels of systemic inflammation compared to healthy individuals. Interestingly, a "young and inflamed" paradox was observed: the youngest patients (≤50 years) exhibited the highest baseline inflammatory markers (Hs-CRP: 32.3 mg/L vs. 16.9 mg/L in controls). This suggests that CAE in younger populations may be driven by a more active inflammatory state.
Multivariate logistic regression confirmed that both Hs-CRP and IL-6 are independent predictors of CAE, with Hs-CRP showing a strong association (OR = 1.782).
Age-Dependent Treatment Response
The efficacy of rosuvastatin treatment followed a clear age gradient. The youngest cohort (CAE-A) experienced the most dramatic improvements, with Hs-CRP levels dropping from 32.3 to 17.5 mg/L ($p=0.0001$) and IL-6 dropping from 12.3 to 6.4 pg/dL ($p=0.021$). In contrast, the oldest group (CAE-C) showed no statistically significant change in inflammatory markers.
Discussion
The findings suggest that younger individuals may be more sensitive to the anti-inflammatory effects of statins, potentially due to higher basal metabolic rates in lipid synthesis and degradation. The lack of significant response in older patients might reflect a more chronic, less reversible inflammatory state or different underlying disease mechanisms.
Limitations
The study is limited by its relatively small sample size for a multi-center trial and the use of angiography rather than more precise imaging modalities like Intravascular Ultrasound (IVUS). Future research should investigate the specific biological pathways that account for this age-dependent sensitivity.
Conclusion
Early intervention with rosuvastatin is highly effective in reducing systemic inflammation in younger patients with coronary artery ectasia. These results underscore the importance of early diagnosis and the prompt initiation of statin therapy to manage the disease effectively.
Summary updated